Annual CFF:
-$5.21B+$12.01B(+69.74%)Summary
- As of today, ABBV annual cash from financing is -$5.21 billion, with the most recent change of +$12.01 billion (+69.74%) on December 31, 2024.
- During the last 3 years, ABBV annual cash from financing has risen by +$13.83 billion (+72.63%).
- ABBV annual cash from financing is now -127.85% below its all-time high of $18.71 billion, reached on December 31, 2019.
Performance
ABBV Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly CFF:
-$4.59B-$1.88B(-69.37%)Summary
- As of today, ABBV quarterly cash from financing is -$4.59 billion, with the most recent change of -$1.88 billion (-69.37%) on September 30, 2025.
- Over the past year, ABBV quarterly cash from financing has dropped by -$1.52 billion (-49.41%).
- ABBV quarterly cash from financing is now -117.25% below its all-time high of $26.60 billion, reached on December 31, 2019.
Performance
ABBV Quarterly Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
-$15.42B-$1.52B(-10.92%)Summary
- As of today, ABBV TTM cash from financing is -$15.42 billion, with the most recent change of -$1.52 billion (-10.92%) on September 30, 2025.
- Over the past year, ABBV TTM cash from financing has dropped by -$12.66 billion (-458.46%).
- ABBV TTM cash from financing is now -171.16% below its all-time high of $21.67 billion, reached on March 31, 2020.
Performance
ABBV TTM Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ABBV Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +69.7% | -49.4% | -458.5% |
| 3Y3 Years | +72.6% | +16.8% | +28.3% |
| 5Y5 Years | -127.8% | -63.1% | -182.0% |
ABBV Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +79.0% | -142.4% | +52.4% | -8812.7% | +39.0% |
| 5Y | 5-Year | -127.8% | +79.0% | -142.4% | +52.4% | -182.0% | +39.0% |
| All-Time | All-Time | -127.8% | +79.0% | -117.3% | +52.4% | -171.2% | +39.0% |
ABBV Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | -$4.59B(-69.4%) | -$15.42B(-10.9%) |
| Jun 2025 | - | -$2.71B(-115.4%) | -$13.90B(+19.6%) |
| Mar 2025 | - | -$1.26B(+81.7%) | -$17.29B(-231.8%) |
| Dec 2024 | -$5.21B(+69.7%) | -$6.86B(-123.3%) | -$5.21B(-88.7%) |
| Sep 2024 | - | -$3.07B(+49.6%) | -$2.76B(-17.5%) |
| Jun 2024 | - | -$6.10B(-156.4%) | -$2.35B(-1258.4%) |
| Mar 2024 | - | $10.82B(+345.3%) | -$173.00M(+99.0%) |
| Dec 2023 | -$17.22B(+30.6%) | -$4.41B(-65.8%) | -$17.18B(+23.3%) |
| Sep 2023 | - | -$2.66B(+32.1%) | -$22.41B(+11.3%) |
| Jun 2023 | - | -$3.92B(+36.7%) | -$25.26B(-5.2%) |
| Mar 2023 | - | -$6.19B(+35.7%) | -$24.02B(+3.1%) |
| Dec 2022 | -$24.80B(-30.3%) | -$9.63B(-74.6%) | -$24.80B(-15.3%) |
| Sep 2022 | - | -$5.52B(-106.0%) | -$21.51B(-9.6%) |
| Jun 2022 | - | -$2.68B(+61.6%) | -$19.63B(+14.0%) |
| Mar 2022 | - | -$6.97B(-10.0%) | -$22.84B(-19.9%) |
| Dec 2021 | -$19.04B(-65.5%) | -$6.34B(-74.0%) | -$19.04B(-16.1%) |
| Sep 2021 | - | -$3.64B(+38.1%) | -$16.40B(-5.3%) |
| Jun 2021 | - | -$5.88B(-85.4%) | -$15.57B(-27.0%) |
| Mar 2021 | - | -$3.17B(+14.1%) | -$12.25B(-6.5%) |
| Dec 2020 | -$11.50B(-161.5%) | -$3.69B(-31.3%) | -$11.50B(-161.2%) |
| Sep 2020 | - | -$2.81B(-9.5%) | $18.80B(-10.5%) |
| Jun 2020 | - | -$2.57B(-6.1%) | $21.00B(-3.1%) |
| Mar 2020 | - | -$2.42B(-109.1%) | $21.67B(+15.8%) |
| Dec 2019 | $18.71B(+230.0%) | $26.60B(+4446.7%) | $18.71B(+259.6%) |
| Sep 2019 | - | -$612.00M(+67.8%) | -$11.72B(-15.0%) |
| Jun 2019 | - | -$1.90B(+64.7%) | -$10.19B(+41.0%) |
| Mar 2019 | - | -$5.38B(-40.7%) | -$17.27B(-20.0%) |
| Dec 2018 | -$14.40B | -$3.83B(-517.6%) | -$14.40B(-15.2%) |
| Sep 2018 | - | $916.00M(+110.2%) | -$12.50B(+12.1%) |
| Jun 2018 | - | -$8.98B(-257.8%) | -$14.22B(-128.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | -$2.51B(-30.1%) | -$6.23B(-13.0%) |
| Dec 2017 | -$5.51B(-40.3%) | -$1.93B(-138.0%) | -$5.51B(+9.4%) |
| Sep 2017 | - | -$810.00M(+17.3%) | -$6.09B(+8.4%) |
| Jun 2017 | - | -$980.00M(+45.4%) | -$6.65B(-47.6%) |
| Mar 2017 | - | -$1.79B(+28.3%) | -$4.50B(-14.6%) |
| Dec 2016 | -$3.93B(-168.3%) | -$2.50B(-82.5%) | -$3.93B(-1.8%) |
| Sep 2016 | - | -$1.37B(-217.8%) | -$3.86B(-8.9%) |
| Jun 2016 | - | $1.16B(+195.5%) | -$3.54B(-164.8%) |
| Mar 2016 | - | -$1.22B(+49.9%) | $5.46B(-5.0%) |
| Dec 2015 | $5.75B(+274.7%) | -$2.43B(-130.2%) | $5.75B(-21.2%) |
| Sep 2015 | - | -$1.06B(-110.4%) | $7.30B(-4.4%) |
| Jun 2015 | - | $10.17B(+1193.4%) | $7.64B(+359.3%) |
| Mar 2015 | - | -$930.00M(-5.4%) | -$2.95B(+10.5%) |
| Dec 2014 | -$3.29B(+4.3%) | -$882.00M(-22.7%) | -$3.29B(-4.3%) |
| Sep 2014 | - | -$719.00M(-73.3%) | -$3.16B(-3.5%) |
| Jun 2014 | - | -$415.00M(+67.5%) | -$3.05B(+2.7%) |
| Mar 2014 | - | -$1.28B(-71.0%) | -$3.14B(+8.9%) |
| Dec 2013 | -$3.44B(-278.2%) | -$747.00M(-21.9%) | -$3.44B(-1023.8%) |
| Sep 2013 | - | -$613.00M(-22.6%) | -$306.29M(-112.0%) |
| Jun 2013 | - | -$500.00M(+68.4%) | $2.55B(+47.9%) |
| Mar 2013 | - | -$1.58B(-166.2%) | $1.73B(-10.7%) |
| Dec 2012 | $1.93B(+128.5%) | $2.39B(+6.4%) | $1.93B(+195.7%) |
| Sep 2012 | - | $2.24B(+269.2%) | -$2.02B(+69.0%) |
| Jun 2012 | - | -$1.33B(+3.6%) | -$6.51B(+6.4%) |
| Mar 2012 | - | -$1.38B(+11.9%) | -$6.96B(-2.6%) |
| Dec 2011 | -$6.78B(>-9900.0%) | -$1.56B(+30.7%) | -$6.78B(-29.9%) |
| Sep 2011 | - | -$2.25B(-26.9%) | -$5.22B(-75.8%) |
| Jun 2011 | - | -$1.77B(-48.3%) | -$2.97B(-148.3%) |
| Mar 2011 | - | -$1.20B | -$1.20B |
| Dec 2010 | $65.00M(+101.3%) | - | - |
| Dec 2009 | -$4.88B | - | - |
FAQ
- What is AbbVie Inc. annual cash from financing?
- What is the all-time high annual cash from financing for AbbVie Inc.?
- What is AbbVie Inc. annual cash from financing year-on-year change?
- What is AbbVie Inc. quarterly cash from financing?
- What is the all-time high quarterly cash from financing for AbbVie Inc.?
- What is AbbVie Inc. quarterly cash from financing year-on-year change?
- What is AbbVie Inc. TTM cash from financing?
- What is the all-time high TTM cash from financing for AbbVie Inc.?
- What is AbbVie Inc. TTM cash from financing year-on-year change?
What is AbbVie Inc. annual cash from financing?
The current annual cash from financing of ABBV is -$5.21B
What is the all-time high annual cash from financing for AbbVie Inc.?
AbbVie Inc. all-time high annual cash from financing is $18.71B
What is AbbVie Inc. annual cash from financing year-on-year change?
Over the past year, ABBV annual cash from financing has changed by +$12.01B (+69.74%)
What is AbbVie Inc. quarterly cash from financing?
The current quarterly cash from financing of ABBV is -$4.59B
What is the all-time high quarterly cash from financing for AbbVie Inc.?
AbbVie Inc. all-time high quarterly cash from financing is $26.60B
What is AbbVie Inc. quarterly cash from financing year-on-year change?
Over the past year, ABBV quarterly cash from financing has changed by -$1.52B (-49.41%)
What is AbbVie Inc. TTM cash from financing?
The current TTM cash from financing of ABBV is -$15.42B
What is the all-time high TTM cash from financing for AbbVie Inc.?
AbbVie Inc. all-time high TTM cash from financing is $21.67B
What is AbbVie Inc. TTM cash from financing year-on-year change?
Over the past year, ABBV TTM cash from financing has changed by -$12.66B (-458.46%)